Search clinical trials for: Combination of Telmisartan and Ramipril

Total 147175 results

Boehringer Ingelheim

Completed

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Cardiovascular Diseases

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand and more
Institut de Recherches Cliniques de Montreal

Terminated

Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes

Hypertension | Type 2 Diabetes | Albuminuria

Canada
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers

Healthy
Catholic University of the Sacred Heart

Unknown

Telmisartan Versus Ramipril After Acute Coronary Syndrome (TERACS)

Myocardial Infarction | Coronary Disease | Acute Coronary Syndrome

Italy
Postgraduate Institute of Medical Education and...

Completed

Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy (START1DM)

Diabetic Nephropathy

India
Novartis Pharmaceuticals

Completed

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

Hypertension

Russian Federation
University of Erlangen-Nürnberg Medical School

Completed

TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Boehringer Ingelheim

Withdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Hypertension

Japan
Boehringer Ingelheim

Completed

Open Label Study Telmisartan and Amlodipine in Hypertension

Hypertension

Belgium, Canada, Denmark, Finland, France, Korea, Republic of, Netherlands, Norway, Philippines, South Africa, Sweden, Taiwan
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Telmisartan, Amlodipine and Combination in Healthy Subjects

Healthy

China
Boehringer Ingelheim

Completed

Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

Hypertension

Belgium, Canada, Denmark, Finland, France, Korea, Republic of, Netherlands, Norway, Philippines, South Africa, Sweden, Taiwan
Boehringer Ingelheim

Completed

Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension

Hypertension

Australia, Austria, Bulgaria, Czech Republic, Ireland, Italy, New Zealand, Russian Federation, Slovakia, Spain, Switzerland, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Telmisartan Tab Hypertension

Hypertension
Boehringer Ingelheim

Completed

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Hypertension

United States, Bulgaria, Czech Republic, France, Hungary, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Ukraine
Boehringer Ingelheim

Completed

Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)

Hypertension
Boehringer Ingelheim

Completed

Telmisartan+Amlodipine Fixed Dose Combination in Hypertension

Hypertension

China
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Healthy
IlDong Pharmaceutical Co Ltd

Completed

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5

Hypertension

France, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Taiwan, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway
Boehringer Ingelheim

Completed

Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Telmisartan and Amlodipine Versus Monocomponent Tablets

Hypertension

Canada
Boehringer Ingelheim

Completed

26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension

Hypertension

Australia, Austria, Bulgaria, Czech Republic, Ireland, Italy, New Zealand, Russian Federation, Slovakia, Spain, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Healthy

Japan
Boehringer Ingelheim

Completed

Filtered Trial for Telmisartan 40mg Non-responder

Hypertension

Japan
Boehringer Ingelheim

Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Hypertension

Japan
Boehringer Ingelheim

Completed

Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension

Hypertension
Yuhan Corporation

Completed

Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Hypertension | Hyperlipidemia

Korea, Republic of
Boehringer Ingelheim

Completed

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

Hypertension

Japan
Boehringer Ingelheim

Completed

Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension

Hypertension
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

Hypertension
Boehringer Ingelheim

Completed

Telmisartan 80mg Non-responder Trial

Hypertension

Japan
Boehringer Ingelheim

Completed

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Hypertension | Diabetes Mellitus, Type 2

Germany, France, Spain
Boehringer Ingelheim

Completed

Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM (PRISMA)

Hypertension

United Kingdom, Switzerland, Austria, France, Germany, Netherlands, South Africa, Spain
Acrobat Trial Group

Unknown

ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT) (ACROBAT)

Hypertension and Atrial Fibrillation

Japan
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Filtered Trial for Amlodipine Non-responder

Hypertension

Japan
Boehringer Ingelheim

Completed

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

Hypertension

United States, Argentina, Canada, Chile, Mexico, Peru
Research Institute for Complex Problems of Cardiovascular...

Completed

Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation

Atrial Fibrillation
Brigham and Women's Hospital

Completed

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Hypertension

United States
Boehringer Ingelheim

Completed

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Hypertension

United States, Canada
Boehringer Ingelheim

Completed

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension (MicCAT)

Hypertension
Bayer

Completed

Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting (POTASSIUM)

Primary Hypertension

Poland
Boehringer Ingelheim

Completed

TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch

Hypertension

Germany, Italy, Mexico, Netherlands, Poland
Yonsei University

Completed

Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome

Hypertension

Korea, Republic of
University of Michigan
Novartis Pharmaceuticals

Withdrawn

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

Hypertension | Metabolic Syndrome

United States
Boehringer Ingelheim

Completed

Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers

Healthy

3

Subscribe